In the latest trading session, Moderna (MRNA) closed at $33.86, marking a -5.66% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%. Meanwhile, the Dow ...

The "Pharmaceutical Current Good Manufacturing Practices (CGMPs) for the 21st Century--A Risk Based Approach" initiative was ...

A lawsuit challenging Health and Human Services Secretary Robert F. Kennedy Jr.'s recommendations on the COVID-19 vaccine can ...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

A new feline muscle health supplement has been launched by Virbac. The market access to Ursolyx Soft Chews for Cats follows ...

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing ...

Holcomb’s bill would add “vaccine status” to the list of reasons protected in law why patients cannot be discriminated ...

A little over a month before her death, Tatiana Schlossberg wrote an essay about her cancer battle where she described RFK Jr ...

One of the most well-studied cellular responses is how they react during times of stress, such as when the temperature gets ...

Stéphane Bancel, CEO of vaccine maker Moderna, addressed shareholders in a letter that dissected the events of 2025 while projecting a positive outlook for the company’s future in 2026 and beyond.

This is a summary of: Liu. H. et al. Viral RNA blocks circularization to evade host codon usage control. Nature https://doi.org/10.1038/s41586-025-09809-y (2025).

Within hours of getting inked, pigments begin migrating through your body, building up in immune tissues and triggering ...